U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT06898970) titled 'Intratumoral Vusolimogene Oderparepvec (VO) in Combination with Pembrolizumab for Angiosarcoma' on March 20.
Brief Summary: This is a multicenter, open-label study of Intratumoral Vusolimogene Oderparepvec (VO) to investigate safety and estimate when used in combination with pembrolizumab for treating participants with angiosarcoma. This is the first study evaluating this novel combination in participants with advanced angiosarcoma who have progressed after prior immunotherapy.
Study Start Date: May 31
Study Type: INTERVENTIONAL
Condition:
Angiosarcoma
Angiosarcoma, Adult
Intervention:
BIOLOGICAL: Vusolimogene Oderparepvec (V...